View On Demand

Innovative Cancer Therapy Company Is Making News

About the Event

Kineta is on the verge of a number of major milestones and has significant news to share on the company’s lead programs, as well as its reverse merger with Yumanity Therapeutics. On this call you’ll learn more about:

  • Upcoming new data on VISTA program, both as a monotherapy and in combination with the blockbuster drug Keytruda
  • Details of the FDA IND approval slated for late October/early November
  • Phase 1/2 clinical trials that will launch near the end of year with data expected in Q4 2023
  • How the reverse merger provides a rare pre-IPO opportunity for the company and investors. The SEC approval should come in late October
  • The company will have five post merger programs have the potential for $2B in milestone payments and up to $8B in royalties from Merck, Genentech, and other partners

Join our webinar to hear from Kineta President, Craig Phillips as he provides detailed updates on all these topics and more. 

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.